Business
Notification of Preliminary Results
Notification of Preliminary Results.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 7450B Evgen Pharma PLC 11 June 2019 \n\n \n\n\n\n\nFor immediate release\n\n\n11 June 2019\n\n\n\n\n \n \n \n \n \n \nEvgen Pharma plc \n (\"Evgen\" or \"the Company\")\n \nNotification of Preliminary Results\nEvgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, will announce its preliminary results for the year ended 31 March 2019 on Thursday 13 June 2019.\n \nEnquiries:\n \n\n\n\n\nEvgen Pharma plc\nDr Stephen Franklin, CEO\nRichard Moulson, CFO\nwww.evgen.com\n \n\n\nc/o +44 (0) 20 7466 5000\n\n\n\n\nfinnCap\nGeoff Nash, Teddy Whiley (Corporate Finance)\nAlice Lane, Manasa Patil (ECM)\nwww.finncap.com\n \n\n\n+44 (0) 20 7220 0500\n\n\n\n\nWG Partners LLP\nNigel Barnes, Claes Spång\n \n\n\n+44 (0) 20 3705 9330\n\n\n\n\nBuchanan\nMark Court, Sophie Wills, Tilly Abraham\[email protected]\n \n\n\n +44 (0) 20 7466 5000\n\n\n\n\nNotes for editors:\nAbout Evgen Pharma plc\nEvgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. \nThe Group commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. \nFor further information, please visit: www.evgen.com\n \n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END NORURSWRKUANAAR\n ","length":4905,"tagName":"div"}]